Literature DB >> 32633076

Minimally invasive hybrid surgery: A salvage tumor enucleation for local recurrence of thoracic esophageal carcinoma after definitive chemoradiotherapy.

Jun Kanamori1, Seiichiro Abe2, Daisuke Kurita1, Koshiro Ishiyama1, Yuki Hirano1, Junya Oguma1, Ichiro Oda2, Yutaka Saito2, Hiroyuki Daiko1.   

Abstract

Local recurrence after definitive chemoradiation for esophageal carcinoma is associated with poor outcomes. Although salvage esophagectomy is a standard treatment that offers a chance of long-term survival, the procedure is associated with high morbidity and mortality. Minimally invasive hybrid surgery (MIHS) employs thoracoscopic and esophagoscopic procedures and is generally used to treat benign esophageal submucosal tumors. A 64-year-old man with thoracic esophageal carcinoma experienced local relapse after definitive chemoradiation. He underwent MIHS and was discharged 18 days after surgery with a slight degree of stricture. Pathological findings revealed squamous cell carcinoma with no residual tumor in the resection margins, and the patient remains free from cancer relapse 24 months after surgery. Here, we report the findings in this patient, in whom MIHS was successfully performed as a salvage tumor enucleation for local recurrence of esophageal carcinoma after definitive chemoradiotherapy.
© 2020 Japan Society for Endoscopic Surgery, Asia Endosurgery Task Force and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  esophageal squamous cell carcinoma; local neoplasm recurrence; minimally invasive surgery

Year:  2020        PMID: 32633076     DOI: 10.1111/ases.12830

Source DB:  PubMed          Journal:  Asian J Endosc Surg        ISSN: 1758-5902


  1 in total

1.  Robotic colorectal surgery using the Senhance® robotic system: a single center experience.

Authors:  N E Samalavicius; A Dulskas; V Janusonis; V Klimasauskiene; V Eismontas; O Deduchovas; T Janusonis; R Markelis; E Smolskas
Journal:  Tech Coloproctol       Date:  2022-03-19       Impact factor: 3.699

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.